In vitro, in vivo and in silico metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant

Bioanalysis

Volumn 8, Issue 1, 2016, Pages 65-82

  Swortwood, Madeleine J ^a   Carlier, Jeremy ^a   Ellefsen, Kayla N ^a,b   Wohlfarth, Ariane ^a,c   Diao, Xingxing ^a   Concheiro Guisan, Marta ^a,d   Kronstrand, Robert ^c,e   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c DEPARTMENT OF FORENSIC GENETICS AND FORENSIC TOXICOLOGY   (Sweden)

^d JOHN JAY COLLEGE OF CRIMINAL JUSTICE   (United States)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

hepatocytes; high resolution MS; metabolism; novel psychoactive substances; synthetic cathinone; PVT

Indexed keywords

ALPHA PYRROLIDINOPENTIOTHIOPHENONE; ALPHA PYRROLIDINOPENTIOTHIOPHENONE 2 KETOPYRROLIDINYL; ALPHA PYRROLIDINOPENTIOTHIOPHENONE DIHYDROXYPYRROLIDINYL; ALPHA PYRROLIDINOPENTIOTHIOPHENONE HYDROXYTHIOPHENYL; ALPHA PYRROLIDINOPENTIOTHIOPHENONE THIOPHENOL; DRUG METABOLITE; GLUCURONIDE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; ALPHA-PYRROLIDINOPENTIOTHIOPHENONE; CENTRAL STIMULANT AGENT; PYRROLIDINE DERIVATIVE;

ARTICLE; COMPUTER MODEL; COMPUTER PROGRAM; DATA MINING; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER CELL; MASS SPECTROMETRY; URINALYSIS; COMPUTER SIMULATION; LIVER MICROSOME; METABOLISM; METABOLOMICS; PROCEDURES; URINE;

CENTRAL NERVOUS SYSTEM STIMULANTS; COMPUTER SIMULATION; DATA MINING; HEPATOCYTES; HUMANS; MASS SPECTROMETRY; METABOLOMICS; MICROSOMES, LIVER; PYRROLIDINES; THIOPHENES;

EID: 84952650130     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.237     Document Type: Article

References (46)

1. European Monitoring Center for Drugs and Drug Addiction. European Monitoring Centre for Drugs and Drug Addiction Publications Office of the European Union, New psychoactive substances in Europe - An update from the EU Early Warning System (March 2015). Publications Office of the European Union, Luxembourg (2015).
2. European Monitoring Center for Drugs and Drug Addiction. World Drug Report 2013. United Nations Office on Drugs and Crime Sales No. E.13.XI.6 18 (2013). Publications Office of the European Union, Luxembourg. www.unodc.org
3. Kelly JP. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal. 3(7-8), 439-453 (2011).
4. Gregg RA, Rawls SM. Behavioral pharmacology of designer cathinones: a review of the preclinical literature. Life Sci. 97(1), 27-30 (2014).
5. Capriola M. Synthetic cathinone abuse. Clin. Pharmacol. 5, 109-115 (2013).
6. Gunderson EW, Kirkpatrick MG, Willing LM, Holstege CP. Substituted cathinone products: a new trend in "bath salts" and other designer stimulant drug use. J. Addict. Med. 7(3), 153-162 (2013).
7. Lehner KR, Baumann MH. Psychoactive bath salts: compounds, mechanisms, and toxicities. Neuropsychopharmacology 38(1), 243-244 (2013).
8. Harrigan T. Schedules of controlled substances: temporary placement of 10 synthetic cathinones into schedule I. Fed. Regist. 79(45), 12938-12943 (2014).
9. Uchiyama N, Matsuda S, Kawamura M, Kikura- Hanajiri R, Goda Y. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol. 31(2), 223-240 (2013).
10. Roesner P. Designer drugs online news: alpha-PVT. Email Newsletter May 8 (2014). www.designer-drugs.de
11. Elliott S, Evans J. A 3-year review of new psychoactive substances in casework. Forensic Sci. Int. 243C, 55-60 (2014).
12. European Monitoring Centre for Drugs and Drug Addiction Publications Office of the European Union. European Drug Report 2014: Trends and Developments. Luxembourg (2014).
13. Baumann MH, Ayestas MA Jr, Partilla JS, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37(5), 1192-1203 (2012).
14. Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive bath salts products. Neuropsychopharmacology 38(4), 552-562 (2013).
15. Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH. Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87, 206-213 (2014).
16. Saha K, Partilla JS, Lehner KR, et al. Secondgeneration mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharmacology 40(6), 1321-1331 (2015).
17. Springer D, Fritschi G, Maurer HH. Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-alphapyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 796(2), 253-266 (2003).
18. Springer D, Fritschi G, Maurer HH. Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 793(2), 377-388 (2003).
19. Springer D, Paul LD, Staack RF, Kraemer T, Maurer HH. Identification of cytochrome p450 enzymes involved in the metabolism of 4′-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes. Drug Metab. Dispos. 31(8), 979-982 (2003).
20. Springer D, Peters FT, Fritschi G, Maurer HH. New designer drug 4′-methyl-alpha-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 789(1), 79-91 (2003).
21. Springer D, Peters FT, Fritschi G, Maurer HH. Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 773(1), 25-33 (2002).
22. Springer D, Peters FT, Fritschi G, Maurer HH. New designer drug 4′-methyl-alpha-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 5(789), 79-91 (2003).
23. Springer D, Staack RF, Paul LD, Kraemer T, Maurer HH. Identification of cytochrome P450 enzymes involved in the metabolism of 4′-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica 33(10), 989-998 (2003).
24. Springer D, Staack RF, Paul LD, Kraemer T, Maurer HH. Identification of cytochrome P450 enzymes involved in the metabolism of 3′,4′-methylenedioxy-alphapyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes. Xenobiotica 35(3), 227-237 (2005).
25. Meyer MR, Du P, Schuster F, Maurer HH. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC- high-resolution MS and its detectability in urine by GC-MS. J. Mass Spectrom. 45(12), 1426-1442 (2010).
26. Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH. New designer drug α-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 44(6), 952-964 (2009).
27. Peters FT, Meyer MR, Theobald DS, Maurer HH. Identification of cytochrome P450 enzymes involved in the metabolism of the new designer drug 4′-methyl-alphapyrrolidinobutyrophenone. Drug Metab. Dispos. 36(1), 163-168 (2008).
28. Zaitsu K, Katagi M, Tsuchihashi H, Ishii A. Recently abused synthetic cathinones, α-pyrrolidinophenone derivatives: a review of their pharmacology, acute toxicity, and metabolism. Forensic Toxicol. 32(1), 1-8 (2014).
29. Takayama T, Suzuki M, Todoroki K, et al. UPLC/ESI-MS/ MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and alpha-PVT, by human liver microsome. Biomed. Chromatogr. 28(6), 831-838 (2014).
30. Ellefsen K, Wohlfarth A, Swortwood M, Diao X, Concheiro M, Huestis M. 4-methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. Forensic Toxicol. doi:10.1007/s11419-015- 0287-4 (2015) (Epub ahead of print).
31. Wohlfarth A, Scheidweiler KB, Pang S, et al. Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. Drug Test Anal. doi:10.1002/dta.1856 (2015) (Epub ahead of print).
32. Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA. High-resolution mass spectrometry for characterizing the metabolism of synthetic cannabinoid THJ-018 and Its 5-fluoro analog THJ-2201 after incubation in human hepatocytes. Clin. Chem. doi:10.1373/clinchem.2015.243535 (2015) (Epub ahead of print).
33. Li AP. Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem. Biol. Interact. 168(1), 16-29 (2007).
34. Strano-Rossi S, Anzillotti L, Dragoni S, et al. Metabolism of JWH-015, JWH-098, JWH-251, and JWH-307 in silico and in vitro: a pilot study for the detection of unknown synthetic cannabinoids metabolites. Anal. Bioanal. Chem. 406(15), 3621-3636 (2014).
35. Concheiro M, Anizan S, Ellefsen K, Huestis MA. Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry. Anal. Bioanal. Chem. 405(29), 9437-9448 (2013).
36. Baranczewski P, Stanczak A, Sundberg K, et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol. Rep. 58(4), 453-472 (2006).
37. Mcnaney CA, Drexler DM, Hnatyshyn SY, et al. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev. Technol. 6(1), 121-129 (2008).
38. Lave T, Dupin S, Schmitt C, et al. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm. Res. 14(2), 152-155 (1997).
39. Atkinson AJ, Jr., Kushner W. Clinical pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 19 105-127 (1979).
40. Tyrkko E, Pelander A, Ketola RA, Ojanpera I. In silico and in vitro metabolism studies support identification of designer drugs in human urine by liquid chromatography/ quadrupole-time-of-flight mass spectrometry. Anal. Bioanal. Chem. 405(21), 6697-6709 (2013).
41. Shima N, Katagi M, Kamata H, et al. Metabolism of the newly encountered designer drug α-pyrrolidinovalerophenone in humans: identification and quantitation of urinary metabolites. Forensic Toxicol. 32(1), 59-67 (2014).
42. Negreira N, Erratico C, Kosjek T, et al. In vitro phase I and phase II metabolism of alpha-pyrrolidinovalerophenone (alpha-PVP), methylenedioxypyrovalerone (MDPV) and methedrone by human liver microsomes and human liver cytosol. Anal. Bioanal. Chem. 407(19), 5803-5816 (2015).
43. Meyer MR, Maurer HH. Metabolism of designer drugs of abuse: an updated review. Curr. Drug Metab. 11(5), 468-482 (2010).
44. Vickers S, Polsky SL. The biotransformation of nitrogen containing xenobiotics to lactams. Curr. Drug Metab. 1(4), 357-389 (2000).
45. Concheiro M, Castaneto M, Kronstrand R, Huestis MA. Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching. J. Chromatogr. A 1397, 32-42 (2015).
46. Marinetti LJ, Antonides HM. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J. Anal. Toxicol. 37(3), 135-146 (2013).